Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma

References

• Mounier M, Bossard N, Remontet L, EUROCARE-5 Working Group.; CENSUR Working Survival Group, et al. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematol. 2015;2:e481–e491.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Marcus R, ESMO Guidelines Committee, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v83–v90.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310.
   PubMed Web of Science ®Google Scholar
• Engelhard M, Stuschke M. Report on workshop: UICC workshop “Therapy of NHL in early stages”. Part 1: follicular lymphoma. Ann Hematol. 2001;80:B13–B15.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Nadel B, Pasqualucci L, et al. Follicular lymphoma: state-of-the-art ICML workshop in Lugano 2015. Hematol Oncol. 2017 [April 4]. doi: 10.1002/hon.2411
   Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, National comprehensive cancer network, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12:1282–1303.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282–1290.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116:3843–3851.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Owen TE, Rubinger M, et al. Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. PLoS One. 2013;8:e65156.
   PubMed Web of Science ®Google Scholar
• Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219–1227.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64:928–934.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Starza ID, Frattarelli N, et al. Stage I/II follicular lymphoma: spread of bcl-2/IgH + cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. Br J Haematol. 2007;137:216–220.
   PubMed Web of Science ®Google Scholar
• Cavalli M, De Novi LA, Della Starza I, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol. 2017;177:588–596.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:2115–2122.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368–3375.
   PubMed Web of Science ®Google Scholar
• Barzenje DA, Cvancarova Småstuen M, Liestøl K, et al. Radiotherapy compared to other strategies in the treatment of Stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One. 2015;10:e0131158.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493–500.
   PubMed Web of Science ®Google Scholar
• Taverna C, Martinelli G, Hitz F, et al. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03. J Clin Oncol. 2016;34:495–500.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424–435.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153–161.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;6:4579–4586.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, International Group of Investigators, et al. German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin’s lymphoma cells. J Radiat Res. 2005;46:241–248.
   PubMed Web of Science ®Google Scholar
• Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res. 2006;47:183–196.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–870.
   PubMed Web of Science ®Google Scholar
• Baues C, Trommer-Nestler M, Jablonska K, et al. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy. 2017;9:423–433.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Ciammella P, Ricardi U. Limited stage follicular lymphoma: current role of radiation therapy. Mediterr J Hematol Infect Dis. 2016;8:e2016041.
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56:2350–2356.
   PubMed Web of Science ®Google Scholar
• Ruella M, Filippi AR, Bruna R, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in Stage I–II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94:783–791.
   PubMed Web of Science ®Google Scholar
• Herfarth K, Engelhard M, Borchmann P, etet al. Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the MIR trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)). Blood. 2012;120:1634.
   Google Scholar
• Cencini E, Fabbri A, Schiattone L, et al. Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma. Leuk Lymphoma. 2015;56:2997–2998.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Marchetti M, Billio A, et al. Expert Panel of the Italian Society of Hematology. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol. 2013;88:185–192.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Luminari S, Ciabatti E, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398–6405.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Marcus R, ESMO Guidelines Working Group, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):iii76–iii82.
   Web of Science ®Google Scholar
• Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28:1388–1395.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121:3325–3334.
   PubMed Web of Science ®Google Scholar
• Macmanus MP, Fisher R, Roos D, et al. CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I–II follicular lymphoma: results of an international randomized trial. Hematol Oncol. 2017;S2:31.
   Google Scholar